ClinicalTrials.Veeva

Menu

The Effects of Autologous Platelet-rich Plasma Supplement During Sperm Cryopreservation on Post-cryopreserved Sperm Quality

R

Rajavithi Hospital

Status

Enrolling

Conditions

Post-cryopreserved Sperm Quality
Autologous Platelet-rich Plasma Supplement
Sperm Cryopreservation
Semen Analysis

Treatments

Biological: autologous platelet-rich plasma supplement
Biological: no autologous platelet-rich plasma supplement

Study type

Interventional

Funder types

Other

Identifiers

NCT06258759
151/2566

Details and patient eligibility

About

Sperm cryopreservation is an essential procedure for male fertility in certain situations, like cancer, vasectomy or other obstructive surgeries, autoimmunity diseases, immunosuppressive therapeutic strategies, or when the male partner is incapable of providing sufficient spermatozoa on the day of egg retrieval. Semen cryopreservation is mainly associated with decreased viability, motility, and DNA damage of spermatozoa due to the osmotic and mechanical stresses attributed to the freezing-thaw- ing process. Sperm cryodamage mainly originates from osmotic changes, cold shock, intracellular ice crystal formation, and oxidative stress. Based on this, some protective strategies have been proposed and developed, even the addition of cryoprotectants. Recently, Platelet-rich plasma (PRP) is becoming very popular in medicine. The therapeutic effect of platelets is related to alpha granule contents. A study showed that PRP modulates ROS toxicity through a different mechanism. VEGF detoxify oxidative damage via activation of the nuclear factor (erythroid- derived 2)-like2 (Nrf2) pathway. Oxidative stress modulation and apoptosis inhibition both have an essential role during the cryopreservation process. In this case, it raises the question of whether PRP can improve the sperm quality against freeze-thawing-induced damage. Therefore, the present study aimed to examine different concentrations of PRP on frozen-thawed sperm parameters of vitality, morphology, motility and DNA fragmentation

Full description

  • Each participant will be collected a semen and PRP.
  • Each semen will be separated into two specimens as the additional autologous platelet-rich plasma supplement group and control group (no adding autologous platelet-rich plasma). Both groups will undergo cryopreservation by Sperm vitrification for 14 days.
  • The additional autologous platelet-rich plasma supplement group: the semen will be added by 5% PRP and mixed with Sperm Freezing Medium and undergo cryopreservation by Sperm vitrification for 14 days.
  • The control group (no adding autologous platelet-rich plasma): the semen will be mixed with Sperm Freezing Medium and undergo cryopreservation by Sperm vitrification for 14 days.
  • After 14 days, the vitrified semen was transferred to a water bath of 37 °C for thawing. And analyzed Semen analysis via Computer Assisted Sperm Analysis: CASA and analyzed DNA fragmentation

Enrollment

20 estimated patients

Sex

Male

Ages

20 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. A man who be a Rajavithi hospital clients or staff.
  2. Aged 20-40 years old.
  3. Has normal semen analysis.
  4. Can communicate and understand Thai language very well.
  5. Voluntarily participated in the research.
  6. Sexual abstinence for 2-7 days.

Exclusion criteria

  1. A man who ever diagnosed with infertile patient.
  2. A wan who diagnosed with any hematological disease such as Coagulation disorders, Hypertension, Thrombocytopenia, Platelet dysfunction.

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

20 participants in 2 patient groups

experimental: semen
Experimental group
Description:
a semen of normal semen analysis
Treatment:
Biological: autologous platelet-rich plasma supplement
placebo: semen
Experimental group
Description:
a semen of normal semen analysis
Treatment:
Biological: no autologous platelet-rich plasma supplement

Trial contacts and locations

1

Loading...

Central trial contact

Nisanart Booning, M.D.; Choermin Thitipatlertdech, M.D.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems